Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elezanumab - AbbVie

Drug Profile

Elezanumab - AbbVie

Alternative Names: ABT-555

Latest Information Update: 26 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action RGMA protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis
  • Phase I Spinal cord injuries

Most Recent Events

  • 20 Feb 2020 AbbVie plans an expanded-access programme for Spinal cord injuries in USA (IV) (NCT04278235)
  • 22 Jan 2019 Phase-II clinical trials in Multiple sclerosis in Canada and USA (IV) (NCT03737812)
  • 11 Dec 2018 Phase-II clinical trials in Multiple sclerosis in USA (IV) (NCT03737851)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top